ProPhase Labs Posts Narrower Q2 Loss
ProPhase Labs (NASDAQ:PRPH), a diversified consumer healthcare and diagnostics company, posted its second-quarter 2025 results on August 13, 2025. The most notable news was a sharp shortfall in GAAP revenue, offset by a much narrower GAAP loss per share compared to expectations. While the company reported an GAAP earnings per share (EPS) loss of $(0.11), this was better than the analyst consensus of $(0.15) GAAP. Revenue (GAAP) was $1.2 million, far under the estimated $3.55 million (GAAP). Despite progress on margins and debt reduction, overall performance in the quarter reflects a company still operating at a diminished scale, with ongoing liquidity pressures and continued core operating losses.
Source: Analyst estimates for the quarter provided by FactSet.
ProPhase Labs develops and markets over-the-counter health supplements and diagnostic tools. Its product lineup includes dietary supplements for consumer health and the BE-Smart™ esophageal cancer diagnostic test, and it has historically generated revenue from its Nebula Genomics whole genome sequencing business. The company is based in Garden City, New York, and previously grew through contract manufacturing, distribution, and a wide range of consumer products.
Source Fool.com
